Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder

Trevor M. Soergel, Mark P. Cain, Rosalia Misseri, Thomas Gardner, Michael Koch, Richard C. Rink, William Strand, Paul Austin, Linda Shortliffe, David Diamond, John Park

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Purpose: Cancer following augmentation cystoplasty is a recognized risk factor. The procedure has only gained popularity in pediatric urology within the last 25 years, limiting the population being studied by statistical power and the lack of long-term followup. The majority of reported cases of post-augmentation malignancy have occurred in adults with multiple risk factors. Currently the most common indication for augmentation cystoplasty in children and adolescents is neuropathic bladder. We review 3 cases of transitional cell carcinoma (TCC) following augmentation cystoplasty in this unique population with no additional risk factors for bladder cancer. Materials and Methods: We reviewed our clinical database of children and adolescents who underwent bladder augmentation since 1978 to evaluate the incidence of cancer. This study represents a captured population within a single institutional practice. There were 483 cases entered into the database, and particular attention was paid to 260 augmentations with at least 10 years of followup. We reviewed medical history, clinical outcomes, cancer risk factors, augmentation type and pathology of the 3 patients who presented with TCC after augmentation cystoplasty. Results: Three patients presented with grade 2 to 3 TCC following bladder augmentation, all of whom underwent exploratory laparotomy and eventually died of metastatic disease. No patient had a history of smoking exposure greater than 10 packs per year or other known risk factors for bladder cancer. Two patients had an ileocecal augmentation and 1 had a cecal augmentation for neuropathic bladder. Patient age at augmentation was 8, 20 and 24 years, and age at diagnosis of TCC was 29, 37 and 44 years, respectively. Mean time from augmentation to TCC was 19 years. Assuming a 10-year lag period before the risk of cancer, in at least 1.2% of bladder augmentation cases in our database cancer has developed. Conclusions: This study supports the hypothesis that bladder augmentation appears to be an independent risk factor for TCC, with a lag time of less than 20 years. We recommend endoscopic surveillance of all patients with a history of bladder augmentation beginning 10 years after initial surgery.

Original languageEnglish
Pages (from-to)1649-1652
Number of pages4
JournalJournal of Urology
Volume172
Issue number4 II
DOIs
StatePublished - Oct 2004

Fingerprint

Neurogenic Urinary Bladder
Transitional Cell Carcinoma
Urinary Bladder
Neoplasms
Databases
Urinary Bladder Neoplasms
Institutional Practice
Population
Urology
Laparotomy
Smoking
Pediatrics
Pathology
Incidence

Keywords

  • Bladder, neurogenic
  • Carcinoma, transitional cell

ASJC Scopus subject areas

  • Urology

Cite this

Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. / Soergel, Trevor M.; Cain, Mark P.; Misseri, Rosalia; Gardner, Thomas; Koch, Michael; Rink, Richard C.; Strand, William; Austin, Paul; Shortliffe, Linda; Diamond, David; Park, John.

In: Journal of Urology, Vol. 172, No. 4 II, 10.2004, p. 1649-1652.

Research output: Contribution to journalArticle

Soergel, TM, Cain, MP, Misseri, R, Gardner, T, Koch, M, Rink, RC, Strand, W, Austin, P, Shortliffe, L, Diamond, D & Park, J 2004, 'Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder', Journal of Urology, vol. 172, no. 4 II, pp. 1649-1652. https://doi.org/10.1097/01.ju.0000140194.87974.56
Soergel, Trevor M. ; Cain, Mark P. ; Misseri, Rosalia ; Gardner, Thomas ; Koch, Michael ; Rink, Richard C. ; Strand, William ; Austin, Paul ; Shortliffe, Linda ; Diamond, David ; Park, John. / Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. In: Journal of Urology. 2004 ; Vol. 172, No. 4 II. pp. 1649-1652.
@article{04c22263601949d590b9518e24114149,
title = "Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder",
abstract = "Purpose: Cancer following augmentation cystoplasty is a recognized risk factor. The procedure has only gained popularity in pediatric urology within the last 25 years, limiting the population being studied by statistical power and the lack of long-term followup. The majority of reported cases of post-augmentation malignancy have occurred in adults with multiple risk factors. Currently the most common indication for augmentation cystoplasty in children and adolescents is neuropathic bladder. We review 3 cases of transitional cell carcinoma (TCC) following augmentation cystoplasty in this unique population with no additional risk factors for bladder cancer. Materials and Methods: We reviewed our clinical database of children and adolescents who underwent bladder augmentation since 1978 to evaluate the incidence of cancer. This study represents a captured population within a single institutional practice. There were 483 cases entered into the database, and particular attention was paid to 260 augmentations with at least 10 years of followup. We reviewed medical history, clinical outcomes, cancer risk factors, augmentation type and pathology of the 3 patients who presented with TCC after augmentation cystoplasty. Results: Three patients presented with grade 2 to 3 TCC following bladder augmentation, all of whom underwent exploratory laparotomy and eventually died of metastatic disease. No patient had a history of smoking exposure greater than 10 packs per year or other known risk factors for bladder cancer. Two patients had an ileocecal augmentation and 1 had a cecal augmentation for neuropathic bladder. Patient age at augmentation was 8, 20 and 24 years, and age at diagnosis of TCC was 29, 37 and 44 years, respectively. Mean time from augmentation to TCC was 19 years. Assuming a 10-year lag period before the risk of cancer, in at least 1.2{\%} of bladder augmentation cases in our database cancer has developed. Conclusions: This study supports the hypothesis that bladder augmentation appears to be an independent risk factor for TCC, with a lag time of less than 20 years. We recommend endoscopic surveillance of all patients with a history of bladder augmentation beginning 10 years after initial surgery.",
keywords = "Bladder, neurogenic, Carcinoma, transitional cell",
author = "Soergel, {Trevor M.} and Cain, {Mark P.} and Rosalia Misseri and Thomas Gardner and Michael Koch and Rink, {Richard C.} and William Strand and Paul Austin and Linda Shortliffe and David Diamond and John Park",
year = "2004",
month = "10",
doi = "10.1097/01.ju.0000140194.87974.56",
language = "English",
volume = "172",
pages = "1649--1652",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4 II",

}

TY - JOUR

T1 - Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder

AU - Soergel, Trevor M.

AU - Cain, Mark P.

AU - Misseri, Rosalia

AU - Gardner, Thomas

AU - Koch, Michael

AU - Rink, Richard C.

AU - Strand, William

AU - Austin, Paul

AU - Shortliffe, Linda

AU - Diamond, David

AU - Park, John

PY - 2004/10

Y1 - 2004/10

N2 - Purpose: Cancer following augmentation cystoplasty is a recognized risk factor. The procedure has only gained popularity in pediatric urology within the last 25 years, limiting the population being studied by statistical power and the lack of long-term followup. The majority of reported cases of post-augmentation malignancy have occurred in adults with multiple risk factors. Currently the most common indication for augmentation cystoplasty in children and adolescents is neuropathic bladder. We review 3 cases of transitional cell carcinoma (TCC) following augmentation cystoplasty in this unique population with no additional risk factors for bladder cancer. Materials and Methods: We reviewed our clinical database of children and adolescents who underwent bladder augmentation since 1978 to evaluate the incidence of cancer. This study represents a captured population within a single institutional practice. There were 483 cases entered into the database, and particular attention was paid to 260 augmentations with at least 10 years of followup. We reviewed medical history, clinical outcomes, cancer risk factors, augmentation type and pathology of the 3 patients who presented with TCC after augmentation cystoplasty. Results: Three patients presented with grade 2 to 3 TCC following bladder augmentation, all of whom underwent exploratory laparotomy and eventually died of metastatic disease. No patient had a history of smoking exposure greater than 10 packs per year or other known risk factors for bladder cancer. Two patients had an ileocecal augmentation and 1 had a cecal augmentation for neuropathic bladder. Patient age at augmentation was 8, 20 and 24 years, and age at diagnosis of TCC was 29, 37 and 44 years, respectively. Mean time from augmentation to TCC was 19 years. Assuming a 10-year lag period before the risk of cancer, in at least 1.2% of bladder augmentation cases in our database cancer has developed. Conclusions: This study supports the hypothesis that bladder augmentation appears to be an independent risk factor for TCC, with a lag time of less than 20 years. We recommend endoscopic surveillance of all patients with a history of bladder augmentation beginning 10 years after initial surgery.

AB - Purpose: Cancer following augmentation cystoplasty is a recognized risk factor. The procedure has only gained popularity in pediatric urology within the last 25 years, limiting the population being studied by statistical power and the lack of long-term followup. The majority of reported cases of post-augmentation malignancy have occurred in adults with multiple risk factors. Currently the most common indication for augmentation cystoplasty in children and adolescents is neuropathic bladder. We review 3 cases of transitional cell carcinoma (TCC) following augmentation cystoplasty in this unique population with no additional risk factors for bladder cancer. Materials and Methods: We reviewed our clinical database of children and adolescents who underwent bladder augmentation since 1978 to evaluate the incidence of cancer. This study represents a captured population within a single institutional practice. There were 483 cases entered into the database, and particular attention was paid to 260 augmentations with at least 10 years of followup. We reviewed medical history, clinical outcomes, cancer risk factors, augmentation type and pathology of the 3 patients who presented with TCC after augmentation cystoplasty. Results: Three patients presented with grade 2 to 3 TCC following bladder augmentation, all of whom underwent exploratory laparotomy and eventually died of metastatic disease. No patient had a history of smoking exposure greater than 10 packs per year or other known risk factors for bladder cancer. Two patients had an ileocecal augmentation and 1 had a cecal augmentation for neuropathic bladder. Patient age at augmentation was 8, 20 and 24 years, and age at diagnosis of TCC was 29, 37 and 44 years, respectively. Mean time from augmentation to TCC was 19 years. Assuming a 10-year lag period before the risk of cancer, in at least 1.2% of bladder augmentation cases in our database cancer has developed. Conclusions: This study supports the hypothesis that bladder augmentation appears to be an independent risk factor for TCC, with a lag time of less than 20 years. We recommend endoscopic surveillance of all patients with a history of bladder augmentation beginning 10 years after initial surgery.

KW - Bladder, neurogenic

KW - Carcinoma, transitional cell

UR - http://www.scopus.com/inward/record.url?scp=4544299833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544299833&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000140194.87974.56

DO - 10.1097/01.ju.0000140194.87974.56

M3 - Article

C2 - 15371782

AN - SCOPUS:4544299833

VL - 172

SP - 1649

EP - 1652

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4 II

ER -